HCV Infection and Chronic Renal Disease

1. Chan ST, Ou JJ. Hepatitis C Virus-Induced Autophagy and Host Innate Immune Response. Viruses. 2017;9(8):224.10.3390/v9080224558048128805674Search in Google Scholar

2. Li H, Huang MH, Jiang JD, Peng ZG. Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy. World J Gastroenterol. 2018;24(47):5297-5311.10.3748/wjg.v24.i47.5297630553030598575Search in Google Scholar

3. Chigbu DI, Loonawat R, Sehgal M, Patel D, Jain P. Hepatitis C Virus Infection: Host – Virus Interaction and Mechanisms of Viral Persistence. Cells. 2019;8(4):376.10.3390/cells8040376652373431027278Search in Google Scholar

4. Wilkins T, Akhtar M, Gititu E, Jalluri C, Ramirez J. Diagnosis and Management of Hepatitis C. Am Fam Physician. 2015;91(12):835-842.Search in Google Scholar

5. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3(2):47-52.10.7150/ijms.3.47Search in Google Scholar

6. Manns MP, Buti M, Gane E, et al. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006.10.1038/nrdp.2017.628252637Search in Google Scholar

7. Coppola N, Alessio L, Onorato L, et al. Epidemiology and management of hepatitis C virus infections in immigrant populations. Infect Dis Poverty. 2019;8(1):17.10.1186/s40249-019-0528-6641937030871599Search in Google Scholar

8. Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol. 2014;20(29):9633-9652.10.3748/wjg.v20.i29.9633412335525110404Search in Google Scholar

9. Di Biagio A, Taramasso L, Cenderello G. Treatment of hepatitis C virus genotype 4 in the DAA era. Virol J. 2018;15(1):180.10.1186/s12985-018-1094-4625114330466446Search in Google Scholar

10. Bostan N, Mahmood T. An overview about hepatitis C: a devastating virus. Crit Rev Microbiol. 2010;36(2):91-133.10.3109/1040841090335745520345213Search in Google Scholar

11. Negro F. Steatosis and insulin resistance in response to treatment of chronic hepatitis C. J Viral Hepat. 2012;19 Suppl 1:42-47.10.1111/j.1365-2893.2011.01523.x22233413Search in Google Scholar

12. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584-2593.10.1001/jama.2012.14487823268517Search in Google Scholar

13. Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain?. Hepatology. 2014;59(6):2403-2412.10.1002/hep.2690524155107Search in Google Scholar

14. Kuna L, Jakab J, Smolic R, Wu GY, Smolic M. HCV Extrahepatic Manifestations. J Clin Transl Hepatol. 2019;7(2):172-182.10.14218/JCTH.2018.00049660984431293918Search in Google Scholar

15. Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol. 2001;75(15):7059-7066.10.1128/JVI.75.15.7059-7066.200111443411435586Search in Google Scholar

16. Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. J Hepatol. 2014;61(1 Suppl):S14-S25.10.1016/j.jhep.2014.06.03525443342Search in Google Scholar

17. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58-S68.10.1016/j.jhep.2014.07.01225443346Search in Google Scholar

18. Kinchen VJ, Bailey JR. Defining Breadth of Hepatitis C Virus Neutralization. Front Immunol. 2018;9:1703.10.3389/fimmu.2018.01703608292330116237Search in Google Scholar

19. Chigbu DI, Loonawat R, Sehgal M, Patel D, Jain P. Hepatitis C Virus Infection: Host – Virus Interaction and Mechanisms of Viral Persistence. Cells. 2019;8(4):376.10.3390/cells8040376652373431027278Search in Google Scholar

20. Baskic D, Vukovic V, Popovic S, et al. Correction: Chronic Hepatitis C: Conspectus of immunological events in the course of fibrosis evolution. PLoS One. 2019;14(8):e0221142.10.1371/journal.pone.0221142668716431393958Search in Google Scholar

21. Khatun M, Ray RB. Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis. Cells. 2019;8(10):1249.10.3390/cells8101249682958631615075Search in Google Scholar

22. Liu X, Xu J, Brenner DA, Kisseleva T. Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts. Curr Pathobiol Rep. 2013;1(3):209-214.10.1007/s40139-013-0018-7375725224000319Search in Google Scholar

23. Spengler U, Nattermann J. Immunopathogenesis in hepatitis C virus cirrhosis. Clin Sci (Lond). 2007;112(3):141-155.10.1042/CS2006017117199558Search in Google Scholar

24. Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA. 2007;297(7):724-732.10.1001/jama.297.7.72417312292Search in Google Scholar

25. Czepiel J, Biesiada G, Mach T. Viral hepatitis C. Pol Arch Med Wewn. 2008;118(12):734-740.10.20452/pamw.542Search in Google Scholar

26. Morozov VA, Lagaye S. Hepatitis C virus: Morphogenesis, infection and therapy. World J Hepatol. 2018;10(2):186-212.10.4254/wjh.v10.i2.186583843929527256Search in Google Scholar

27. Dias C, Pipa S, Mota M. Acute hepatitis C from heterosexual transmission. IDCases. 2018;14:e00448.10.1016/j.idcr.2018.e00448612576130191131Search in Google Scholar

28. Blackard JT, Shata MT, Shire NJ, Sherman KE. Acute hepatitis C virus infection: a chronic problem [published correction appears in Hepatology. 2008 Feb;47(2):769]. Hepatology. 2008;47(1):321-331.10.1002/hep.21902227749618161707Search in Google Scholar

29. Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic Manifestations of Hepatitis C: A Metaanalysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology. 2016;150(7):1599-1608.10.1053/j.gastro.2016.02.03926924097Search in Google Scholar

30. Sayiner M, Golabi P, Farhat F, Younossi ZM. Dermatologic Manifestations of Chronic Hepatitis C Infection. Clin Liver Dis. 2017;21(3):555-564.10.1016/j.cld.2017.03.01028689593Search in Google Scholar

31. Cacoub P, Comarmond C, Desbois AC, Saadoun D. Rheumatologic Manifestations of Hepatitis C Virus Infection. Clin Liver Dis. 2017;21(3):455-464.10.1016/j.cld.2017.03.00228689585Search in Google Scholar

32. Goossens N, Negro F. Cardiovascular Manifestations of Hepatitis C Virus. Clin Liver Dis. 2017;21(3):465-473.10.1016/j.cld.2017.03.00328689586Search in Google Scholar

33. Mapoure NY, Budzi MN, Eloumou SAFB, Malongue A, Okalla C, Luma HN. Neurological manifestations in chronic hepatitis C patients receiving care in a reference hospital in sub-Saharan Africa: A cross-sectional study. PLoS One. 2018;13(3):e0192406.10.1371/journal.pone.0192406584165529513678Search in Google Scholar

34. Couronné L, Bachy E, Roulland S, et al. From hepatitis C virus infection to B-cell lymphoma. Ann Oncol. 2018;29(1):92-100.10.1093/annonc/mdx63529045541Search in Google Scholar

35. Flores-Chávez A, Carrion JA, Forns X, Ramos-Casals M. Extrahepatic manifestations associated with Chronic Hepatitis C Virus Infection. Rev Esp Sanid Penit. 2017;19(3):87-97.Search in Google Scholar

36. Tang L, Marcell L, Kottilil S. Systemic manifestations of hepatitis C infection. Infect Agent Cancer. 2016;11:29.10.1186/s13027-016-0076-7487804027222662Search in Google Scholar

37. Ozkok A, Yildiz A. Hepatitis C virus associated glomerulopathies. World J Gastroenterol. 2014;20(24):7544-7554.10.3748/wjg.v20.i24.7544406928624976695Search in Google Scholar

38. Park H, Chen C, Wang W, Henry L, Cook RL, Nelson DR. Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. Hepatology. 2018;67(2):492-504.10.1002/hep.29505581473028873225Search in Google Scholar

39. Guss D, Sherigar J, Rosen P, Mohanty SR. Diagnosis and Management of Hepatitis C Infection in Primary Care Settings. J Gen Intern Med. 2018;33(4):551-557.10.1007/s11606-017-4280-y588077129352420Search in Google Scholar

40. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012;26(4):401-412.10.1016/j.bpg.2012.09.00923199500Search in Google Scholar

41. Karnsakul W, Schwarz KB. Hepatitis B and C. Pediatr Clin North Am. 2017;64(3):641-658.10.1016/j.pcl.2017.01.007543326228502443Search in Google Scholar

42. Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat. 2009;16(2):75-90.10.1111/j.1365-2893.2008.01012.x275998718761607Search in Google Scholar

43. González-Grande R, Jiménez-Pérez M, González Arjona C, Mostazo Torres J. New approaches in the treatment of hepatitis C. World J Gastroenterol. 2016;22(4):1421-1432.10.3748/wjg.v22.i4.1421472197726819511Search in Google Scholar

44. Tsukiyama-Kohara K, Kohara M. Hepatitis C Virus: Viral Quasispecies and Genotypes. Int J Mol Sci. 2017;19(1):23.10.3390/ijms19010023579597429271914Search in Google Scholar

45. Simonović Babić J, Bojović K, Fabri M, Cvejić T, Svorcan P, Noţić D, Jovanović M, Škrbić R, Stojiljković MP, Mijailović Ţ. A real-life data on the efficacy and safety of ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in patients with genotype 1 chronic hepatitis C virus infection in Serbia. Vojnosanit Pregl. 2019; 76(5): 531–536.10.2298/VSP170727186SSearch in Google Scholar

46. Kim S, Han KH, Ahn SH. Hepatitis C Virus and Antiviral Drug Resistance. Gut Liver. 2016;10(6):890-895.10.5009/gnl15573508792727784846Search in Google Scholar

47. Heim MH. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol. 2013;13(7):535-542.10.1038/nri346323743475Search in Google Scholar

48. Bojovic K, Simonovic-Babic J, Mijailovic Z, et al. Micro- elimination of HCV as a possible therapeutic strategy: our experience and a review of literature. J Infect Dev Ctries. 2020;14(2):117-124.10.3855/jidc.1178532146444Search in Google Scholar

49. Akchurin OM. Chronic Kidney Disease and Dietary Measures to Improve Outcomes. Pediatr Clin North Am. 2019;66(1):247-267.10.1016/j.pcl.2018.09.007662397330454747Search in Google Scholar

50. Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim Care. 2008;35(2):329-vii.10.1016/j.pop.2008.01.008247478618486718Search in Google Scholar

51. Cobo G, Lindholm B, Stenvinkel P. Chronic inflammation in end-stage renal disease and dialysis. Nephrol Dial Transplant. 2018;33(suppl_3):iii35-iii40.10.1093/ndt/gfy175616880130281126Search in Google Scholar

52. Fraser SD, Blakeman T. Chronic kidney disease: identification and management in primary care. Pragmat Obs Res. 2016;7:21-32.10.2147/POR.S97310508776627822135Search in Google Scholar

53. Ishigami J, Matsushita K. Clinical epidemiology of infectious disease among patients with chronic kidney disease [published correction appears in Clin Exp Nephrol. 2019 Mar 2;:]. Clin Exp Nephrol. 2019;23(4):437-447.10.1007/s10157-018-1641-8643562630178234Search in Google Scholar

54. Razmaria AA. Chronic Kidney Disease. JAMA. 2016;315(20):2248.10.1001/jama.2016.142627218648Search in Google Scholar

55. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2017;389(10075):1238-1252.10.1016/S0140-6736(16)32064-5Search in Google Scholar

56. Breyer MD, Susztak K. Developing Treatments for Chronic Kidney Disease in the 21st Century. Semin Nephrol. 2016;36(6):436-447.10.1016/j.semnephrol.2016.08.001542340427987541Search in Google Scholar

57. Petrović D, Miloradović V, Poskurica M, Stojimirović B. Srp Arh Celok Lek. 2011;139(3-4):248-255.10.2298/SARH1104248PSearch in Google Scholar

58. Lee WC, Lee YT, Li LC, et al. The Number of Comorbidities Predicts Renal Outcomes in Patients with Stage 3–5 Chronic Kidney Disease. J Clin Med. 2018;7(12):493.10.3390/jcm7120493630690630486496Search in Google Scholar

59. Reichel H, Zee J, Tu C, et al. Chronic kidney disease progression and mortality risk profiles in Germany: results from the Chronic Kidney Disease Outcomes and Practice Patterns Study. Nephrol Dial Transplant. 2020;35(5):803-810.10.1093/ndt/gfz260720356031953939Search in Google Scholar

60. Wigneswaran J, Van Wyck D, Pegues D, Gholam P, Nissenson AR. Hepatitis C virus infection in patients with end-stage renal disease. Hemodial Int. 2018;22(3):297-307.10.1111/hdi.1267230141571Search in Google Scholar

61. Lukic R, Gajovic N, Jovanovic I, Jurisevic M, Mijailovic Z, Maric V, Popovska Jovicic B, Arsenijevic N. Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients. Disease Markers olume 2017; 2017:Article ID 627598710.1155/2017/6275987540556928487598Search in Google Scholar

62. Azmi AN, Tan SS, Mohamed R. Hepatitis C and kidney disease: An overview and approach to management. World J Hepatol. 2015;7(1):78-92.10.4254/wjh.v7.i1.78429519725624999Search in Google Scholar

63. Caragea DC, Mihailovici AR, Streba CT, et al. Hepatitis C Infection in Hemodialysis Patients. Curr Health Sci J. 2018;44(2):107-112.Search in Google Scholar

64. Lukic R, Cupic M, Gajovic N, et al. Increased systemic sST2 in patients with end stage renal disease contributes to milder liver damage during HCV infection. J Infect Dev Ctries. 2020;14(5):519-526.10.3855/jidc.1174132525839Search in Google Scholar

65. Nguyen DB, Bixler D, Patel PR. Transmission of hepatitis C virus in the dialysis setting and strategies for its prevention. Semin Dial. 2019;32(2):127-134.10.1111/sdi.12761641105530569604Search in Google Scholar

66. Cacoub P, Desbois AC, Isnard-Bagnis C, Rocatello D, Ferri C. Hepatitis C virus infection and chronic kidney disease: Time for reappraisal. J Hepatol. 2016;65(1 Suppl):S82-S94.10.1016/j.jhep.2016.06.01127641990Search in Google Scholar

67. Henson JB, Sise ME. The association of hepatitis C infection with the onset of CKD and progression into ESRD. Semin Dial. 2019;32(2):108-118.10.1111/sdi.12759641072830496620Search in Google Scholar